UMDNJ, Proteonomix commence screening of patients with ESLD for use in UMK-121 clinical trial

Published on November 21, 2012 at 3:00 AM · No Comments

PROTEONOMIX, INC. (OTCBB: PROT), a biotechnology company (the "Company") focused on developing therapeutics based upon the use of human cells and their derivatives, announced today that the University of Medicine & Dentistry of New Jersey (UMDNJ) in conjunction with the Company has commenced the screening of patients with End Stage Liver Disease (ESLD) for use in its clinical trial of UMK-121.

Michael Cohen, the Chief Executive Officer of the Company stated: "At least thirty (30) patients have been screened so far pursuant to inclusion and exclusion criteria approved by the Institutional Review Board as part of the protocol.  The initiation of screening is the first step towards commencement of the clinical trial of UMK-121."

Source:

Proteonomix, Inc.

Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | Русский | Svenska | Polski
Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post
You might also like... ×
Splice-switching oligonucleotide drugs alter editing of gene transcript